• Leukemias, lymphomas, and other hematologic cancers

Oncaspar Generic Name & Formulations

General Description

Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free.

Pharmacological Class

Asparagine-specific enzyme.

How Supplied

Single-dose vial (5mL)—1

Generic Availability


Oncaspar Indications


First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity), as part of a multi-agent chemotherapy regimen.

Oncaspar Dosage and Administration

Adults and Children

Premedicate with APAP, diphenhydramine, and famotidine 30–60mins prior to initiation. Give by IV inj over 1–2hrs or by IM inj (max 2mL/inj site). Treat every 14 days. ≤21yrs: 2500 IU/m2. >21yrs: 2000 IU/m2. Dose modifications: see full labeling.

Oncaspar Contraindications


History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy. Severe hepatic impairment.

Oncaspar Boxed Warnings

Not Applicable

Oncaspar Warnings/Precautions


Observe patients for 1hr post-dose. Have medical treatment for anaphylaxis readily available. Permanently discontinue for Grade 3/4 infusion/hypersensitivity reactions, confirmed pancreatitis, or severe thrombosis. Monitor bilirubin and transaminases at least weekly during treatment cycles through at least 6wks after last dose. Monitor serum glucose, coagulation parameters. Discontinue if severe hemorrhage or liver toxicity occurs. Advise females of reproductive potential to use effective non-hormonal contraception during and for 3months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1month after last dose).

Oncaspar Pharmacokinetics

See Literature

Oncaspar Interactions


May increase the risk of glucocorticoid-induced toxicities.

Oncaspar Adverse Reactions

Adverse Reactions

Hypoalbuminemia, elevated transaminases/bilirubin, febrile neutropenia, hypertriglyceridemia, hyperglycemia, pancreatitis, coagulopathy, embolic/thrombotic events, hypersensitivity.

Oncaspar Clinical Trials

See Literature

Oncaspar Note

Not Applicable

Oncaspar Patient Counseling

See Literature